» Articles » PMID: 24406300

Biobanking 3.0: Evidence Based and Customer Focused Biobanking

Overview
Journal Clin Biochem
Specialty Biochemistry
Date 2014 Jan 11
PMID 24406300
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Biobanking is a new and very dynamic field. To achieve long term financial sustainability of biobank infrastructures we propose that a new focus is needed on activities, products and services provided by the biobank that relate to the external stakeholder: biobanking 3.0. Earlier stages of biobanking are biobanking 1.0 (primary focus on the number of biospecimens and data) and biobanking 2.0 (primary focus on the quality of biospecimens and data). Both stages 1.0 and 2.0 are predominantly product oriented areas and have required a mostly internal focus on operational development within the biobank itself. In this paper we will introduce our concept of biobanking 3.0 which capitalizes on the earlier stages but dictates a shift in focus to enhancing the value and impact for the three major sets of external stakeholders (people/patients, funders, and research customers) and creating a path to balanced and planned investment in biobank infrastructure and the sustainability of biobanking. Biobanking 3.0 will improve real understanding as well as perceptions of value across different stakeholders. Patients and donors will appreciate seeing how their biospecimens and data are effectively used for research. Funders will value the ability to plan efficient targeting of funding and to monitor the impact of their support. Researchers will capitalize on the ability to translate their ideas into effective knowledge. Ultimately adoption of biobanking 3.0 will impact on the sustainability in the three main dimensions relevant to biobanking: social sustainability (acceptability), operational sustainability (efficiency), and financial sustainability (accomplishment).

Citing Articles

Risk mapping for better governance in biobanking: the case of biobank.cy.

Akyuz K, Goisauf M, Martin G, Mayrhofer M, Antoniou S, Charalambidou G Front Genet. 2024; 15:1397156.

PMID: 38948356 PMC: 11211562. DOI: 10.3389/fgene.2024.1397156.


Banking on a new understanding: translational opportunities from veterinary biobanks.

LaLonde-Paul D, Mouttham L, Promislow D, Castelhano M Geroscience. 2023; 45(3):1439-1450.

PMID: 36890420 PMC: 10400517. DOI: 10.1007/s11357-023-00763-z.


Real-life data from standardized preanalytical coding (SPREC) in tissue biobanking and its dual use for sample characterization and process optimization.

Skoworonska M, Blank A, Centeno I, Hammer C, Perren A, Zlobec I J Pathol Clin Res. 2022; 9(2):137-148.

PMID: 36484086 PMC: 9896154. DOI: 10.1002/cjp2.305.


Purpose, Partnership, and Possibilities: The Implementation of the Dog Aging Project Biobank.

Mouttham L, Castelhano M Biomark Insights. 2022; 17:11772719221137217.

PMID: 36468152 PMC: 9716607. DOI: 10.1177/11772719221137217.


Banking on the Last Gift: Cornell's Signature Program of Postmortem Tissue Procurement.

Garrison S, Mouttham L, Castelhano M Biopreserv Biobank. 2022; 21(1):46-55.

PMID: 35930257 PMC: 9963475. DOI: 10.1089/bio.2021.0103.